Table 3:
Primary hemostasis, coagulation and inflammatory parameters* according to ABO blood type, factor V Leiden R506Q and prothrombin G20210A in the Copenhagen General Population Study†
| Characteristic | ABO blood type, mean ± SE | Factor V Leiden R506Q, mean ± SE | Prothrombin G20210A, mean ± SE | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||||
| O n = 22 403 (39%) | Non-O n = 34 557 (61%) | p value‡ | Noncarrier n = 52 103 (91%) | Heterozygous n = 4 730 (8%) | Homozygous n = 127 (0.2%) | p value‡ | Noncarrier n = 55 770 (98%) | Heterozygous n = 1 183 (2%) | Homozygous n = 6 (0.01%)§ | p value‡ | |
| Primary hemostasis | |||||||||||
|
| |||||||||||
| Platelets, 109/L | 280 ± 0.5 | 281 ± 0.4 | 0.1 | 281 ± 0.3 | 280 ± 1.0 | 281 ± 6.3 | 0.6 | 281 ± 0.3 | 285 ± 2.1 | 275 ± 27 | 0.1 |
|
| |||||||||||
| Mean platelet volume, fL | 7.7 ± 0.006 | 7.7 ± 0.005 | 0.3 | 7.7 ± 0.004 | 7.7 ± 0.01 | 7.6 ± 0.07 | 0.5 | 7.7 ± 0.004 | 7.7 ± 0.03 | 8.1 ± 0.5 | 0.3 |
|
| |||||||||||
| Coagulation | |||||||||||
|
| |||||||||||
| INR, ratio | 0.993 ± 0.002 0.994 ± 0.001 | < 0.001 | 0.992 ± 0.001 | 1.010 ± 0.004 | 1.119 ± 0.043 | 0.1 | 0.994 ± 0.001 | 0.991 ± 0.009 | 1.008 ± 0.039 | < 0.001 | |
|
| |||||||||||
| Coagulation factor | 103.38 ± 0.16 103.68 ± 0.13 | 0.02 | 103.63 ± 0.1 | 103.04 ± 0.4 | 94.88 ± 3.1 | 0.4 | 103.50 ± 0.1 | 106.76 ± 0.8 | 97.00 ± 14 | < 0.001 | |
|
| |||||||||||
| II + VII + X, % | |||||||||||
|
| |||||||||||
| APTT, s | 29.4 ± 0.03 | 28.4 ± 0.02 | < 0.001 | 28.8 ± 0.02 | 28.8 ± 0.06 | 29.0 ± 0.32 | 0.6 | 28.8 ± 0.02 | 29.9 ± 0.1 | 30.5 ± 1.3 | < 0.001 |
|
| |||||||||||
| Fibrinogen, μmol/L | 11 ± 0.02 | 11 ± 0.02 | 0.1 | 11 ± 0.01 | 11 ± 0.04 | 11 ± 0.35 | 0.2 | 11 ± 0.01 | 11 ± 0.08 | 10 ± 0.62 | 0.02 |
|
| |||||||||||
| Inflammation | |||||||||||
|
| |||||||||||
| CRP, mg/L | 2.7 ± 0.03 | 2.8 ± 0.03 | 0.05 | 2.7 ± 0.02 | 2.6 ± 0.06 | 3.3 ± 0.83 | 0.5 | 2.7 ± 0.02 | 2.9 ± 0.15 | 2.5 ± 1.24 | 0.01 |
|
| |||||||||||
| Leukocytes, 109/L | 7.42 ± 0.02 | 7.38 ± 0.01 | 0.01 | 7.39 ± 0.01 | 7.43 ± 0.03 | 7.44 ± 0.16 | 0.03 | 7.39 ± 0.01 | 7.43 ± 0.06 | 6.38 ± 0.50 | 0.6 |
|
| |||||||||||
| Complement C3, g/L | 1.14 ± 0.001 | 1.15 ± 0.001 | < 0.001 | 1.14 ± 0.001 | 1.14 ± 0.003 | 1.16 ± 0.021 | 1.0 | 1.14 ± 0.001 | 1.15 ± 0.006 | 1.08 ± 0.080 | 0.1 |
Note: APTT = activated partial thromboplastin time, CRP = C-reactive protein, INR = international normalized ratio, SE = standard error.
*
Unadjusted values from study entry are presented because we were examining differences by genotypes usually unconfounded by cardiovascular risk factors.
†
Numbers vary slightly depending on availability of measurements.
‡
Wilcoxen rank sum tests and tests for trend.
§
One homozygous participant receiving warfarin was excluded.